Dissolution Testing under USP <711>

Dissolution testing measures the rate at which a drug substance is released from a solid dosage form into solution under standardised, controlled...

Dissolution testing measures the rate at which a drug substance is released from a solid dosage form into solution under standardised, controlled conditions, and serves several distinct but related purposes: routine quality control confirmation of batch consistency, support for in-vitro–in-vivo correlation modelling, and, where an appropriately validated method exists, support for bioequivalence assessment following manufacturing or formulation changes. The design of a dissolution method begins with clear definition of its intended objective, since a method optimised for routine quality control discrimination may differ substantially from one designed to support a biowaiver or IVIVC claim.

Selection of an appropriate dissolution medium is governed fundamentally by the requirement to maintain sink conditions throughout the test, conventionally defined as the drug's solubility in the chosen medium exceeding three times the concentration that would result from complete dissolution of the administered dose, ensuring that the observed dissolution rate reflects the intrinsic performance of the dosage form rather than being artificially limited by the solubility capacity of the test medium itself. The pharmacopoeial media most commonly employed span the physiological pH range encountered along the gastrointestinal tract: 0.1 normal hydrochloric acid, at pH 1.2, simulates gastric fluid and is particularly relevant for acidic drugs and for confirming the integrity of enteric coatings; acetate buffer at pH 4.5 approximates upper intestinal conditions and is informative for weakly basic drugs; phosphate buffer at pH 6.8 represents the most widely employed medium for immediate-release tablets, reflecting intestinal conditions and being the medium generally preferred by the United States Food and Drug Administration; and phosphate buffer at pH 7.4 approximates blood or rectal conditions and is frequently employed to confirm dissolution behaviour of enteric-coated products following gastric exposure. For poorly soluble BCS Class II and IV drugs, surfactant-modified media, incorporating sodium lauryl sulfate at 0.1 to 1.0 per cent or polysorbate 80 at 0.01 to 0.5 per cent, are frequently required to achieve adequate sink conditions.

USP <711> describes several standardised apparatus configurations, of which Apparatus I, the rotating basket, and Apparatus II, the rotating paddle, are by far the most widely employed for solid oral dosage forms, while additional apparatus configurations exist for specialised applications including transdermal systems, extended-release formulations, and osmotic pump devices. Following selection of apparatus and medium, method parameters including rotation speed, sampling time points, and sample volume are optimised to provide adequate discrimination between formulations of differing quality while remaining robust to the normal variability of routine manufacturing, before the finalised method undergoes formal analytical validation encompassing specificity, linearity, accuracy, precision, and robustness, together with confirmation that the method possesses adequate stability-indicating capability where intended to support such claims.